These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31415503)

  • 1. A unified national cardiovascular disease (CVD) risk generator is required to address equity in the management of CVD risk in clinical practice in New Zealand.
    Kerr A; Wells S; Moffitt A; Lund M; Kreichbaum J; Harwood M; Jackson R
    N Z Med J; 2019 Aug; 132(1500):89-94. PubMed ID: 31415503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1).
    Bannink L; Wells S; Broad J; Riddell T; Jackson R
    N Z Med J; 2006 Nov; 119(1245):U2313. PubMed ID: 17146488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Pylypchuk R; Wells S; Kerr A; Poppe K; Riddell T; Harwood M; Exeter D; Mehta S; Grey C; Wu BP; Metcalf P; Warren J; Harrison J; Marshall R; Jackson R
    Lancet; 2018 May; 391(10133):1897-1907. PubMed ID: 29735391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of New Zealand CVD risk chart adjustments for family history and ethnicity on eligibility for treatment (PREDICT CVD-5).
    Wells S; Kerr A; Broad J; Riddell T; Kenealy T; Jackson R
    N Z Med J; 2007 Sep; 120(1261):U2712. PubMed ID: 17853933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10.
    Riddell T; Wells S; Jackson R; Lee AW; Crengle S; Bramley D; Ameratunga S; Pylypchuk R; Broad J; Marshall R; Kerr A
    N Z Med J; 2010 Feb; 123(1309):50-61. PubMed ID: 20186242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of alternative cardiovascular risk prediction equations for population health planning: a routine health data linkage study of 1.7 million New Zealanders.
    Mehta S; Jackson R; Pylypchuk R; Poppe K; Wells S; Kerr AJ
    Int J Epidemiol; 2018 Oct; 47(5):1571-1584. PubMed ID: 30010781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease.
    Poppe KK; Doughty RN; Wells S; Gentles D; Hemingway H; Jackson R; Kerr AJ
    Heart; 2017 Jun; 103(12):891-892. PubMed ID: 28232378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
    Metcalf PA; Wells S; Scragg RK; Jackson R
    N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice.
    Wells S; Furness S; Rafter N; Horn E; Whittaker R; Stewart A; Moodabe K; Roseman P; Selak V; Bramley D; Jackson R
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):173-8. PubMed ID: 18391644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated prevalence of cardiovascular disease and distribution of cardiovascular risk in New Zealanders: data for healthcare planners, funders, and providers.
    Wells S; Broad J; Jackson R
    N Z Med J; 2006 Apr; 119(1232):U1935. PubMed ID: 16633394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do cardiovascular risk prediction equations developed among 30-74 year olds perform in older age groups? A validation study in 125 000 people aged 75-89 years.
    Mehta S; Jackson R; Poppe K; Kerr AJ; Pylypchuk R; Wells S
    J Epidemiol Community Health; 2020 Jun; 74(6):527-533. PubMed ID: 32144211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and population description of the CREDENCE study: cardiovascular risk equations for diabetes patients from New Zealand and Chinese electronic health records.
    Liang J; Pylypchuk R; Tang X; Shen P; Liu X; Chen Y; Tan J; Wu J; Zhang J; Lu P; Lin H; Gao P; Jackson R
    Eur J Epidemiol; 2021 Oct; 36(10):1085-1095. PubMed ID: 34420154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Movers and stayers: The geography of residential mobility and CVD hospitalisations in Auckland, New Zealand.
    Exeter DJ; Sabel CE; Hanham G; Lee AC; Wells S
    Soc Sci Med; 2015 May; 133():331-9. PubMed ID: 25483929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of CVD risk equations for older patients assessed in general practice: a cohort study.
    Wells S; Pylypchuk R; Mehta S; Kerr A; Selak V; Poppe K; Grey C; Jackson R
    N Z Med J; 2020 Jun; 133(1517):32-55. PubMed ID: 32595220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.
    Robinson T; Jackson R; Wells S; Kerr A; Marshall R
    N Z Med J; 2017 Oct; 130(1463):28-38. PubMed ID: 28981492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Māori/non-Māori differences in cardiovascular disease risk and risk management in routine primary care practice using web-based clinical decision support: (PREDICT CVD-2).
    Riddell T; Jackson RT; Wells S; Broad J; Bannink L
    N Z Med J; 2007 Mar; 120(1250):U2445. PubMed ID: 17339901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk.
    Schilling C; Knight J; Mortimer D; Petrie D; Clarke P; Chalmers J; Kerr A; Jackson R
    Health Policy; 2017 Dec; 121(12):1233-1239. PubMed ID: 29042060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between estimated glomerular filtration rate and incident cardiovascular disease in an ethnically diverse primary care cohort.
    Church E; Poppe K; Harwood M; Mehta S; Grey C; Selak V; Marshall MR; Wells S
    N Z Med J; 2019 Mar; 132(1491):11-26. PubMed ID: 30845125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.